Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

被引：0
|
作者：
Salles, Gilles [1 ]
Wang, Anthony [2 ]
Mutebi, Alex [3 ]
Alshreef, Abualbishr [2 ]
Davies, Kalatu R. [2 ]
van de Wetering, Gijs [4 ]
Chirikov, Viktor [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Genmab, Princeton, NJ USA
[4] Open Hlth, Bethesda, MD USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10934 / 10935
页数：2
相关论文
共 50 条
  • [31] Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
    van Imhoff, Gustaaf W.
    McMillan, Andrew
    Matasar, Matthew J.
    Radford, John
    Ardeshna, Kirit M.
    Kuliczkowski, Kazimierz
    Kim, WonSeog
    Hong, Xiaonan
    Goerloev, Jette Soenderskov
    Davies, Andrew
    Caballero Barrigon, Maria Dolores
    Ogura, Michinori
    Leppa, Sirpa
    Fennessy, Michael
    Liao, Qiming
    van der Holt, Bronno
    Lisby, Steen
    Hagenbeek, Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (05) : 544 - +
  • [32] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [33] NEW TREATMENT FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2021, 121 (06) : 21 - 22
  • [34] Tisagenlecleucel Approved in Relapsed/Refractory Large B-Cell Lymphoma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (06) : 397 - 397
  • [35] IMPROVEMENTS IN SYMPTOMS, IMPACT OF TREATMENT, AND SATISFACTION WITH TREATMENT AMONG PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA TREATED WITH SUBCUTANEOUS EPCORITAMAB
    Kosa, K.
    Mutebi, A.
    Wang, A.
    Blaedel, J.
    Sacchi, M.
    Martin, S.
    VALUE IN HEALTH, 2023, 26 (06) : S315 - S315
  • [36] Choosing a CAR for Relapsed/Refractory Large B-cell Lymphoma
    Abramson, Jeremy S.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10): : 621 - 622
  • [37] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [38] Epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 longer-term data
    Izutsu, K.
    Kumode, T.
    Yuda, J.
    Nagai, H.
    Mishima, Y.
    Suehiro, Y.
    Yamamoto, K.
    Fujisaki, T.
    Ishitsuka, K.
    Ishizawa, K.
    Ikezoe, T.
    Nishikori, M.
    Akahane, D.
    Fujita, J.
    Jafarinasabian, P.
    Noguchi, H.
    Buchbjerg, J.
    Favaro, E.
    Fukuhara, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1324 - S1325
  • [39] Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
    Li, Tommy
    Gibiansky, Leonid
    Parikh, Apurvasena
    van der Linden, Marcel
    Sanghavi, Kinjal
    Putnins, Matthew
    Sacchi, Mariana
    Feng, Huaibao
    Ahmadi, Tahamtan
    Gupta, Manish
    Xu, Steven
    CLINICAL PHARMACOKINETICS, 2025, 64 (01) : 127 - 141
  • [40] Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
    Zhang, Huilai
    Zhou, Keshu
    Cheng, Ying
    Zhang, Liling
    Yang, Haiyan
    Zou, Liqun
    Cao, Junning
    Huang, Huiqiang
    Guo, Ye
    Wang, Zhao
    Huang, Sha
    Liang, Zhiyu
    Yao, Hui
    Guo, Haiyi
    Fang, Yiqian
    Zhu, Hongjie
    BLOOD, 2022, 140 : 3750 - 3751
12345